Small (Weinheim an der Bergstrasse, Germany)Cathepsin BHumansProteolysisAnimalsCell Line
Development and Mechanistic Evaluation of Cathepsin B-Activatable Peptide-Drug Conjugate PROTACs for Targeted Protein Degradation in Malignant Tumors: Advancing Precision Protein Degradation Therapeutics in Oncology.
Qingqing Zhang, Yu Liu, Jie Zhang, Hengtao Dong, Xiaoyan Pan, Jie Zhang
Published: 202610.1002/smll.202506562
Abstract
Since the advent of proteolysis targeting chimeras (PROTACs), both small molecule PROTACs and peptide-based PROTACs have exhibited distinct advantages. However, PROTACs still exist issues such as poor membrane permeability, low bioavailability, and p…
Preview only. Read the full abstract at the source